Anlon Healthcare IPO Gets Over 3.3x Subscription On Day 2: Should You Apply? Check GMP, Other Details | Ipo News


Last Updated:

Anlon Healthcare IPO GMP: Its grey market premium stands at 5.49%, indicating a weak listing.

font
Anlon Healthcare IPO GMP.

Anlon Healthcare IPO GMP.

Anlon Healthcare IPO GMP: The initial public offering of chemical manufacturing company Anlon Healthcare Ltd witnessed its second day of bidding today, Thursday, August 28. The price of the Rs 121.03-crore IPO has been fixed in the range of Rs 86 to Rs 91 per share. Till 6:00 pm on the second day of bidding on Thursday, the issue received a 3.30x subscription, garnering bids for 4,39,44,948 shares as against the 1,33,00,000 shares on offer.

The retail and NII participation stood at 22.33x and 2.09x, respectively. The QIB category was subscribed by 1.01x.

Also Read: Vikran Engineering IPO Gets Over 3x Subscription On Day 2 So Far: Apply Or Not? Check GMP, Reviews

The IPO’s grey market premium on Thursday stood at 5.49%, indicating a weak listing.

Anlon Healthcare IPO Price And Lot Size

The price of the IPO has been fixed in the range of Rs 86 to Rs 91 per share.

For investors, the minimum lot size for the IPO is 164. It means investors will have to apply for a minimum of 164 shares or in multiple thereof. So, retail investors require a minimum capital of Rs 14,924 to apply for the IPO.

Anlon Healthcare IPO Key Dates

The IPO will remain open for public subscription between August 26, 2025, and August 29, 2025. The share allotment will likely be finalised on September 1, and the company is expected to be listed on both BSE and NSE on September 3.

Anlon Healthcare IPO GMP Today

According to market observers, unlisted shares of Anlon Healthcare Ltd are currently trading at Rs 96 against the upper IPO price of Rs 91. It means a grey market premium or GMP of Rs 5, which is 5.49% over its issue price, indicating a mild listing gains.

The GMP is based on market sentiments and keeps changing. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.

Anlon Healthcare IPO: Should You Apply?

Brokerages have largely given a positive response to Anlon Healthcare’s public issue, though with some caution on valuations.

According to Anand Rathi Research, “Anlon Healthcare operates on a scalable business model that allows it to expand its offerings and cater to evolving industry requirements consistently. Additionally, the company has built a well-established and growing customer base.”

The brokerage highlighted that the healthcare sector carries high entry and exit barriers due to long approval timelines and stringent regulatory compliance.

“At the upper price band, the company is valued at P/E of 19.0x to its FY25 earnings, with EV/EBITDA of 16.7x and market cap of Rs 4,836 million post issue of equity shares,” it added, assigning a ‘Subscribe – Long Term’ rating.

Arihant Capital also gave a positive view, saying, “Anlon Healthcare is positioned to benefit from its diverse product portfolio, regulatory approvals and planned capacity expansion.” While long customer approval cycles promote client stickiness, the brokerage cautioned that they could delay new client acquisition.

“At the upper band of Rs 91, the issue is valued at a P/E ratio of 24x, based on annualised PAT of FY25 EPS of Rs 3.9. We are recommending a ‘Subscribe’ rating for this issue,” Arihant Capital said.

Anlon Healthcare IPO: More Details

The issue size is 1,33,00,000 equity shares with a face value of Rs 10 each with a price band of Rs 86 to Rs 91 per share.

The net proceeds from the IPO will be utilised towards funding capital expenditure requirements for its manufacturing facility, full or part-repayment and/or prepayment of certain outstanding secured borrowings availed by the company, funding the working capital requirements, and general corporate purposes.

The book running lead manager to the issue is Interactive Financial Services Limited, and the registrar is Kfin Technologies Ltd.

Anlon Healthcare Limited is a chemical manufacturing company engaged in producing high-purity advanced pharmaceutical intermediates.

authorimg

Mohammad Haris

Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h…Read More

Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h… Read More

News business » ipo Anlon Healthcare IPO Gets Over 3.3x Subscription On Day 2: Should You Apply? Check GMP, Other Details
Disclaimer: Comments reflect users’ views, not News18’s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Read More



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *